Lorenzo Zaffiri, MD;, PhD
Basic profileLorenzo Zaffiri is a Respiratory physician affiliated with Emory University. OpenAlex indexes 94 publications with 1,068 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- KAMADA LTD.Program year20249 payments$5,381
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20231 payment$1,438
- Inari Medical, Inc.Program year20231 payment$207
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
42.2%Macrolide Antimicrobial17.5%Azithromycin100%Part D≥76 patientsShort-acting sulfonamides15.6%Sulfamethoxazole-Trimethoprim100%Part D≥79 patients+ 6 more classes in this area
Metabolism & gastrointestinal
22.1%Proton pump inhibitor8.9%Pantoprazole Sodium79%Omeprazole13%Lansoprazole7%Part D<11 patientsCorticosteroid7.7%Prednisone100%Part D≥44 patients+ 6 more classes in this area
Nervous system
11.7%Gabapentinoids7%Gabapentin92%Pregabalin8%Part D<11 patientsSSRI2.8%Trazodone Hcl58%Escitalopram Oxalate23%Citalopram Hbr18%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Mapping the mTOR pathway in lung transplantation: Is it time for a biomarker-driven precision therapy?
The Journal of Heart and Lung Transplantation
2026 - Donor-Derived Transmissions 2023: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)
American Journal of Transplantation
2025 - Impact of minimally invasive lung transplantation on early outcomes and analgesia use: A matched cohort study
The Journal of Heart and Lung Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Allan Levey, MD
Emory University
Craig Coopersmith, MD
Emory University
James Lah, MD
Emory University
Vasilis Babaliaros, MD
Emory University
Justin Oldham, MD
University of Michigan
Fernando Martinez, MD
University of Massachusetts Chan Medical School
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”